02407 高視醫療
GAUSH MEDITECH
GAUSH MEDITECH
| Listing Date | 2022/12/12 |
| Listing Price | 51.400 |
Quote
Subscription Result
- Subscription Rate1.52x
- Guarantee One Lot Size1 lot
- One Lot Success Rate100%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Gaush Meditech Ltd is the largest domestic player and the fourth largest player in terms of revenue in 2021 with a market share of 6.7% in China’s ophthalmic medical device market with over 20 years of track record.
--
Its product offering covers all seven ophthalmology sub-specialties where ophthalmic medical devices are utilized for their diagnosis, treatment or surgeries, being vitreoretinal diseases, cataracts, refractive surgery, glaucoma, ocular surface diseases, optometry and pediatric ophthalmology. Its product portfolio comprised Distribution Products of its brand partners and Proprietary Products which it develops and manufactures.
--
For the six months ended June 30, 2022, the revenue contribution of its Distribution Products accounted for 70.5% of revenue from sales of products. It had collaborated with 19 overseas brand partners including Heidelberg, Schwind and Optos.
--
As of 20 Nov 2022, the Group had registered ten invention patents and 20 utility patents in China. over 4,000 end customers in China including over 1,200 Class III hospitals and 1,500 Class II hospitals. It had assisted brand partners to obtain the NMPA registration of 72 products.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 13.07M shares |
| No. of International Offer Shares | 11.76M shares |
| No. of HK Offer Shares | 1.31M shares |
| Offer Price | $51.40 |
| Stock Code | 2407 |
| Sponsor(s) | Morgan Stanley Asia Limited, Haitong International Capital Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, Haitong International Securities Company Limited, Daiwa Capital Markets Hong Kong Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Maxa Capital Limited, Sinomax Securities Limited |
TIME TABLE
| Application Period | Nov 30 (Wed) - noon, Dec 05 (Mon) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Dec 09 (Fri) |
| Result Announcement Date | On or before Dec 09 (Fri) |
| Dealings in Shares commence on | Dec 12, 2022. (Mon) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $51.40 |
| Capitalization | 7.60B |
| NAV / share ($) | $1.75 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 51.4, the net proceeds raised would be HKD 283.10M, of which |
| 38.2% : Improve research and development capability and accelerate the commercialization of patents |
| 29% : Improve production capacity and strengthen manufacturing capabilities |
| 9.5% : Expand sales and marketing |
| 10.6% : Working capital |
| 12.7% : Repay interest-bearing borrowings |
IPO NEWS
| 12/12/2022 16:08 |
| {New Stock}GAUSH MEDITECH(02407) ends flat at HK$51.4 |
| 12/12/2022 09:20 |
| {New Stock}GAUSH MEDITECH opens down 0.39% at HK$51.2 |
| 09/12/2022 18:35 |
| {New Stock}GAUSH MEDITECH ends down 3.5% on grey market |
| 09/12/2022 16:20 |
| {New Stock}GAUSH MEDITECH down 4.67% at HK$49 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).